Advances in Aurora kinase inhibitor patents

Expert Opinion on Therapeutic Patents

Volumn 19, Issue 3, 2009, Pages 321-356

  Coumar, Mohane Selvaraj ^a   Cheung, Chun Hei Antonio ^b   Chang, Jang Yang ^b   Hsieh, Hsing Pang ^a  

^a Division of Biotechnology and Pharmaceutical Research   (Taiwan)

^b NATIONAL HEALTH RESEARCH INSTITUTES   (Taiwan)

Author keywords

AT9283; Aurora kinase inhibitors; AZD1152; CHR 3520; ENMD 2076; GSK1070916; MLN8054 MLN8237; MP529; PF 3814735; PHA739358; R763; SNS 314; VX 680 MK0457

Indexed keywords

2 [[3 [4 [5 [2 (3 FLUOROANILINO) 2 OXOETHYL] 1H PYRAZOL 3 YLAMINO] 7 QUINAZOLINYLOXY]PROPYL](ETHYL)AMINO]ETHYL DIHYDROGEN PHOSPHATE; 4 [[9 CHLORO 7 (2,6 DIFLUOROPHENYL) 5H PYRIMIDO[5,4 D][2]BENZAZEPIN 2 YL]AMINO]BENZOIC ACID; AT 9283; AURORA KINASE INHIBITOR; BENZAZOLE; CCT 129202; CHR 3520; CYC 116; CYCLOPROPANECARBOXYLIC ACID [4 [4 (4 METHYL 1 PIPERAZINYL) 6 (5 METHYL 2H PYRAZOL 3 YLAMINO) 2 PYRIMIDINYLTHIO]PHENYL]AMIDE; DIHYDROPYRIDINE DERIVATIVE; ENMD 2076; ENMD 981693; GSK 1070916; HESPERADIN; IMATINIB; IMIDAZOLE DERIVATIVE; IMIDAZOPYRIDINE DERIVATIVE; INDOLINONE DERIVATIVE; JNJ 7706621; MLN 8237; MP 529; N [4 [6 METHOXY 7 (3 MORPHOLINOPROPOXY) 4 QUINAZOLINYLAMINO]PHENYL]BENZAMIDE; PACLITAXEL; PF 3814735; PHA 680632; PHA 739358; PYRAZOLOPYRIMIDINE DERIVATIVE; R 763; SNS 314; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ADVANCED CANCER; CELL DIVISION; CELL PROLIFERATION; CLINICAL TRIAL; CONCENTRATION RESPONSE; CRYSTAL STRUCTURE; DRUG MECHANISM; DRUG SAFETY; DRUG STRUCTURE; ENZYME INHIBITION; HUMAN; LEUKEMIA; NEOPLASM; NONHUMAN; PATENT; QT PROLONGATION; REVIEW; SOLID TUMOR; STRUCTURE ACTIVITY RELATION;

ANIMALS; DRUG DELIVERY SYSTEMS; DRUG DESIGN; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MITOSIS; NEOPLASMS; PATENTS AS TOPIC; PROTEIN KINASE INHIBITORS; PROTEIN-SERINE-THREONINE KINASES;

EID: 67649408925     PISSN: 13543776     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543770802646949     Document Type: Review

References (166)

1. Cancer: Key facts. July 2008. Available from: http://www.who.int/ mediacentre/factsheets/fs297/en/index.html [Accessed 1 August 2008]
2. Keen N, Taylor S. Aurora-kinase inhibitors as anticancer agents. Nat Rev Cancer 2004;4(12):927-936 (Pubitemid 39626216)
3. Vader G, Lens SM. The Aurora kinase family in cell division and cancer. Biochim Biophys Acta 2008;1786(1):60-72
4. Gautschi O, Heighway J, Mack PC, et al. Aurora kinases as anticancer drug targets. Clin Cancer Res 2008;14(6):1639-1648
5. Fu J, Bian M, Jiang Q, Zhang C. Roles of Aurora kinases in mitosis and tumorigenesis. Mol Cancer Res 2007;5(1):1-10 (Pubitemid 46246762)
6. Agnese V, Bazan V, Fiorentino FP, et al. The role of Aurora-A inhibitors in cancer therapy. Ann Oncol 2007;18(Suppl 6):vi47-52
7. Girdler F, Gascoigne KE, Eyers PA, et al. Validating Aurora B as an anti-cancer drug target. J Cell Sci 2006;119(Pt 17):3664-3675 (Pubitemid 44501870)
8. Carpinelli P, Moll J. Aurora kinases and their inhibitors: more than one target and one drug. Adv Exp Med Biol 2008;610:54-73
9. Carpinelli P, Moll J. Aurora kinase inhibitors: identification and preclinical validation of their biomarkers. Expert Opin Ther Targets 2008;12(1):69-80 (Pubitemid 351247163)
10. Mahadevan D, Bearss DJ, Vankayalapati H. Structure-based design of novel anti-cancer agents targeting aurora kinases. Curr Med Chem Anticancer Agents 2003;3(1):25-34 (Pubitemid 36131632)
11. Mortlock AA, Keen NJ, Jung FH, et al. Progress in the development of selective inhibitors of aurora kinases. Curr Top Med Chem 2005;5(8):807-821 (Pubitemid 41183689)
12. Matthews N, Visintin C, Hartzoulakis B, et al. Aurora A and B kinases as targets for cancer: will they be selective for tumors? Expert Rev Anticancer Ther 2006;6(1):109-120
13. Vertex Pharma Inc. US7361492; 2008
14. Vertex Pharma Inc. WO03092607A2; 2004
15. Vertex Pharma Inc. WO04000833A1; 2003
16. Wang Y, Serradell N. VX-680/MK-0457. Drugs Future 2007;32(2):144-147
17. Cheetham GM, Charlton PA, Golec JM, Pollard JR. Structural basis for potent inhibition of the Aurora kinases and a T315I multi-drug resistant mutant form of Abl kinase by VX-680. Cancer Lett 2007;251(2):323-329 (Pubitemid 46669805)
18. Young MA, Shah NP, Chao LH, et al. Structure of the kinase domain of an imatinib-resistant Abl mutant in complex with the Aurora kinase inhibitor VX-680. Cancer Res 2006;66(2):1007-1014 (Pubitemid 43168337)
19. Vertex Pharma Inc. WO07056163A2; 2007
20. Vertex Pharma Inc. WO07056164A2; 2007
21. Vertex Pharma Inc. WO07056221A2; 2007
22. Vertex Pharma Inc. WO07059299A1; 2007
23. Vertex Pharma Inc. WO07022384A2; 2007
24. AstraZeneca AB. US7214518; 2002
25. AstraZeneca AB. WO03055491A1; 2002
26. AstraZeneca AB. US20050070561A1; 2002
27. AstraZeneca AB. WO04058781A1; 2004
28. AstraZeneca AB. WO04094410A1; 2004
29. AstraZeneca AB. WO04105764A1; 2004
30. AstraZeneca AB. WO04058752A1; 2004
31. AstraZeneca AB. WO04113324A1; 2004
32. AstraZeneca AB. WO06129064A1; 2006
33. AstraZeneca AB. WO07083096A2; 2007
34. Heron NM, Anderson M, Blowers DP, et al. SAR and inhibitor complex structure determination of a novel class of potent and specific Aurora kinase inhibitors. Bioorg Med Chem Lett 2006;16(5):1320-1323 (Pubitemid 43143015)
35. Jung FH, Pasquet G, Lambert-Van der Brempt C, et al. Discovery of novel and potent thiazoloquinazolines as selective Aurora A and B kinase inhibitors. J Med Chem 2006;49(3):955-970 (Pubitemid 43221644)
36. Mortlock AA, Foote KM, Heron NM, et al. Discovery, synthesis, and in vivo activity of a new class of pyrazoloquinazolines as selective inhibitors of aurora B kinase. J Med Chem 2007;50(9):2213-2224 (Pubitemid 46683074)
37. Pfizer Italia S.R.L. US7141568; 2006
38. Fancelli D, Berta D, Bindi S, et al. Potent and selective Aurora inhibitors identified by the expansion of a novel scaffold for protein kinase inhibition. J Med Chem 2005;48(8):3080-3084 (Pubitemid 40548120)
39. Fancelli D, Moll J, Varasi M, et al. 1,4,5,6-tetrahydropyrrolo[3,4-c] pyrazoles: identification of a potent Aurora kinase inhibitor with a favorable antitumor kinase inhibition profile. J Med Chem 2006;49(24):7247-7251
40. Pharmacia Italia S.P.A. WO04007504A1; 2004
41. Pharmacia Italia S.P.A. WO05074922A1; 2005
42. Nerviano Medical Sciences S.R.L. WO07009898A1; 2007
43. Nerviano Medical Sciences S.R.L. WO07138017A1; 2007
44. Millennium Pharmaceuticals Inc. WO05111039A2; 2005
45. Millennium Pharmaceuticals Inc. WO08063525A1; 2008
46. Sells T, Ecsedy JA, Stroud SG, et al. MLN8237: an Orally Active Small Molecule Inhibitor of Aurora A kinase in Phase I clinical trials. AACR Annual Meeting (Meeting Abstracts); 2008 April 12-16; San Francisco, CA; 2008
47. Millennium Pharmaceuticals Inc. WO08021038A2; 2008
48. Millennium Pharmaceuticals Inc. WO06041773A2; 2006
49. Cyclacel Ltd. WO04043953A1; 2004
50. Cyclacel Ltd. WO05012298A1; 2004
51. Cyclacel Ltd. WO05075468A2; 2005
52. Cyclacel Ltd. WO06075152A1; 2006
53. Cyclacel Ltd. WO07042786A2; 2007
54. Cyclacel Ltd. WO07042784A2; 2007
55. Griffiths G, Scaerou F, Sorrell D, et al. Anti-tumor activity of CYC116, a novel small molecule inhibition of Aurora kinases and VEGFR2. AACR Annual Meeting (Meeting Abstracts); 2008 April 12-16; San Francisco, CA; 2008
56. Sunesis Pharmaceuticals Inc. WO06036266A1; 2006
57. Sunesis Pharmaceuticals Inc. WO07013964A1; 2007
58. Oslob JD, Romanowski MJ, Allen DA, et al. Discovery of a potent and selective Aurora kinase inhibitor. Bioorg Med Chem Lett 2008;18(17):4880-4884
59. Gamo K, Belmont B, Tangonan B, et al. SNS-314, a novel small-molecule Aurora kinase inhibitor, induces cell-cycle defects and potently supresses tumor growth. AACR Annual Meeting (Meeting Abstracts); 2008 April 12-16; San Francisco, CA; 2008
60. Smithkline Beecham Co. US7282588; 2007
61. Yang J, Anderson K, Hardwicke MA, et al. Biochemical characterization of GSK1070916, a potent and selective inhibitor of Aurora B kinase with extremely AACR Annual Meeting (Meeting Abstracts); 2008 April 12-16; San Francisco, CA; 2008
62. Smithkline Beecham Co. WO07018941A2; 2007
63. Smithkline Beecham Co. WO07024843A2; 2007
64. Smithkline Beecham Co. WO04112719A2; 2004
65. Pfizer Products Inc. WO06067614A2; 2006
66. Pfizer Products Inc. WO07072158A2; 2007
67. Bhattacharya S, Wishka D, Luzzio M, et al. SAR and chemistry of Aurora kinase inhibitors: Discovery of PF-3814735, an oral clinical candidate. AACR Annual Meeting (Meeting Abstracts); 2008 April 12-16; San Francisco, CA; 2008
68. University of Arizona and Montigen Pharmaceuticals Inc. US7312226; 2007
69. University of Arizona and Supergen Inc. US7326712; 2008
70. University of Arizona and Supergen Inc. US7326713; 2008
71. University of Arizona and Supergen Inc. US7335662; 2008
72. Warner SL, Bashyam S, Vankayalapati H, et al. Identification of a lead small-molecule inhibitor of the Aurora kinases using a structure-assisted, fragment-based approach. Mol Cancer Ther 2006;5(7):1764-1773 (Pubitemid 44323244)
73. Supergen Inc. WO06116733A2; 2006
74. Supergen Inc. WO08055233A1; 2008
75. Miikana Therapeutics Inc. WO06055831A2; 2006
76. Miikana Therapeutics Inc. WO07041358A2; 2007
77. Bray MR. ENMD-981693: An oral, aurora kinase - angiogenesis inhibitor. Drug Discovery and Development of Innovative Therapeutics (Meeting Abstracts); 2007 August 6-9; Boston, MA; 2007
78. Bray MR. ENMD-2076, an oral Aurora A and angiogenesis kinase inhibitor. AACR Annual Meeting (Meeting Abstracts); 2008 April 12-16; San Francisco, CA; 2008
79. Astex Technology Ltd. WO05002552A2; 2005
80. Astex Technology Ltd. WO06003440A1; 2006
81. Astex Technology Ltd. WO06070195A1; 2006
82. Astex Technology Ltd. WO06070198A1; 2006
83. Astex Technology Ltd. WO06070202A1; 2006
84. Astex Technology Ltd. WO07077435A1; 2007
85. Astex Technology Ltd. WO08001101A2; 2008
86. Astex Technology Ltd. WO08001115A2; 2008
87. Astex Technology Ltd. WO06070192A1; 2006
88. Rigel Pharmaceuticals Inc. WO05118544A2; 2005
89. Rigel Pharmaceuticals Inc. WO06055561A2; 2006
90. Chroma Therapeutics Ltd. WO06117552A1; 2006
91. Chroma Therapeutics Ltd. WO06117570A1; 2006
92. Chroma Therapeutics Ltd. WO07072017A2; 2007
93. Chan F, Sun C, Perumal M, et al. Mechanism of action of the Aurora kinase inhibitor CCT129202 and in vivo quantification of biological activity. Mol Cancer Ther 2007;6(12 Pt 1):3147-3157
94. Bavetsias V, Sun C, Bouloc N, et al. Hit generation and exploration: imidazo[4,5-b]pyridine derivatives as inhibitors of Aurora kinases. Bioorg Med Chem Lett 2007;17(23):6567-6571
95. Boehringer Ingelheim Pharma KG. US6638965; 2003
96. Boehringer Ingelheim International GMBH. WO07122219A1; 2007
97. Boehringer Ingelheim International GMBH. US20070032514A1; 2007
98. Boehringer Ingelheim International GMBH. WO07115999A1; 2007
99. Ortho McNeil Pharmaceutical Inc. US6924302; 2001
100. Janssen Pharmaceutica N.V. WO06042215A1; 2006
101. Lin R, Connolly PJ, Huang S, et al. 1-Acyl-1H-[1,2,4]triazole-3,5-diamine analogues as novel and potent anticancer cyclin-dependent kinase inhibitors: synthesis and evaluation of biological activities. J Med Chem 2005;48(13):4208-4211
102. Janssen Pharmaceutica N.V. WO06050076A1; 2006
103. Janssen Pharmaceutica N.V. WO06074984A1; 2006
104. Janssen Pharmaceutica N.V. WO06074985A1; 2006
105. Janssen Pharmaceutica N.V. WWO07047646A2; 2007
106. Hughes TV, Emanuel SL, O'Grady HR, et al. 7-[1H-Indol-2-yl]-2,3-dihydro- isoindol-1-ones as dual Aurora-A/VEGF-R2 kinase inhibitors: design, synthesis, and biological activity. Bioorg Med Chem Lett 2008;18(18):5130-5133
107. Hoff Hoffmann-La Roche Inc. US7285569; 2007
108. F Hoffmann-La Roche AG. WO06108489A1; 2006
109. F Hoffmann-La Roche AG. WO07068465A1; 2007
110. F Hoffmann-La Roche AG. WO06063841A2; 2006
111. F Hoffmann-La Roche AG. WO07107346A1; 2007
112. F Hoffmann-La Roche AG. WO06108488A1; 2006
113. F Hoffmann-La Roche AG. WO08022747A1; 2008
114. F Hoffmann-La Roche AG. WO06133885A1; 2006
115. Genentech Inc and Hoffman La Roche Inc. WO07022102A2; 2007
116. Genentech Inc. WO07120333A2; 2007
117. Rawson TE, Ruth M, Blackwood E, et al. A pentacyclic aurora kinase inhibitor (AKI-001) with high in vivo potency and oral bioavailability. J Med Chem 2008;51(15):4465-4475
118. Hoffman-La Roche Inc. US7226923; 2007
119. F Hoffmann-La Roche AG. WO07107298A1; 2007
120. F Hoffmann-La Roche AG. WO08017465A1; 2008
121. Genentech Inc. WO07120339A1; 2007
122. Genentech Inc. WO08079719A1; 2008
123. Bristol-Myers Squibb Company. US20070004731A1; 2007
124. Bristol-Myers Squibb Company. US7232901; 2007
125. Bristol-Myers Squibb Company. US7402582; 2008
126. Bristol-Myers Squibb Company. US7405213; 2008
127. Bristol-Myers Squibb Company. WO07005630A1; 2007
128. Bristol-Myers Squibb Company. WO08083398A2; 2008
129. Bristol-Myers Squibb Company. WO08086264A1; 2008
130. Takeda San Diego Inc. WO06023931A2; 2006
131. Takeda San Diego Inc. WO06044687A2; 2006
132. Takeda San Diego Inc. WO07117995A2; 2007
133. Takeda San Diego Inc. WO07044779A1; 2007
134. Takeda San Diego Inc. WO08045834A2; 2008
135. Bayer Pharmaceuticals Co. WO07064932A2; 2007
136. Schering Co. WO08057512A2; 2008
137. Schering AG. US20070191393A1; 2007
138. Bayer Schering Pharma AG. US20080058358A1; 2008
139. Bayer Schering Pharma AG. US20080167330A1; 2008
140. Mitsubishi Tanabe Pharma Co. WO06118231A1; 2006
141. Mitsubishi Tanabe Pharma Co. WO08053812A1; 2008
142. Mitsubishi Pharma Co. WO05113550A1; 2005
143. Banyu Pharmaceutical Co Ltd. US20080027042A1; 2008
144. Banyu Pharmaceutical Co Ltd. WO08026768A1; 2008
145. Amgen Inc. WO05113494A2; 2005
146. Amgen Inc. WO07100646A1; 2007
147. Amgen Inc. WO07087276A1; 2007
148. Amgen Inc. WO08057280A1; 2008
149. European Molecular Biology Laboratory (EMBL). WO05040368A2; 2005
150. European Molecular Biology Laboratory (EMBL). WO07113005A2; 2007
151. European Molecular Biology Laboratory (EMBL). WO07115805A2; 2007
152. IRM LLC WO07016228A2; 2007
153. Andersen CB, Wan Y, Chang JW, et al. Discovery of selective aminothiazole aurora kinase inhibitors. ACS Chem Biol 2008;3(3):180-192
154. CrystalGenomics Inc. WO07073117A1; 2007
155. CrystalGenomics Inc. WO07083978A1; 2007
156. Aventis Pharma S.A. WO07012972A2; 2007
157. Biogen Idec Inc. WO08094602A2; 2008
158. Nissan Chemical Industries Ltd. WO08001883A1; 2008
159. Praecis Pharmaceuticals Inc. WO08016547A2; 2008
160. TransTech Pharma Inc. WO07095124A2; 2007
161. TranstechPharma. Available from: http://www.ttpharma.com/pipeline-kinase. html [Cited 27th Sept 2008]
162. Coumar MS, Wu JS, Leou JS, et al. Aurora kinase A inhibitors: identification, SAR exploration and molecular modeling of 6,7-dihydro-4H- pyrazolo-[1,5-a] pyrrolo[3,4-d]pyrimidine-5,8-dione scaffold. Bioorg Med Chem Lett 2008;18(5):1623-1627
163. Deng XQ, Wang HY, Zhao YL, et al. Pharmacophore modelling and virtual screening for identification of new Aurora-A kinase inhibitors. Chem Biol Drug Des 2008;71(6):533-539 (Pubitemid 351704053)
164. Coumar MS, Leou JS, Shukla P, et al. Structure-based drug design of novel Aurora kinase A inhibitors: Structure basis for potency and specificity. J Med Chem (Under Revision); 2008
165. Emanuel S, Rugg CA, Gruninger RH, et al. The in vitro and in vivo effects of JNJ-7706621: a dual inhibitor of cyclin-dependent kinases and aurora kinases. Cancer Res 2005;65(19):9038-9046 (Pubitemid 41377396)
166. Myrianthopoulos V, Magiatis P, Ferandin Y, et al. An integrated computational approach to the phenomenon of potent and selective inhibition of aurora kinases B and C by a series of 7-substituted indirubins. J Med Chem 2007;50(17):4027-4037 (Pubitemid 47301735)